Laboratory evaluation of twelve portable devices for medicine quality screening
Open Access
- 30 September 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (9) , e0009360
Abstract
Background: Post-market surveillance is a key regulatory function to prevent substandard and falsified (SF) medicines from being consumed by patients. Field deployable technologies offer the potential for rapid objective screening for SF medicines.Methods and findings: We evaluated twelve devices: three near infrared spectrometers (MicroPHAZIR RX, NIR-S-G1, Neospectra 2.5), two Raman spectrometers (Progeny, TruScan RM), one mid-infrared spectrometer (4500a), one disposable colorimetric assay (Paper Analytical Devices, PAD), one disposable immunoassay (Rapid Diagnostic Test, RDT), one portable liquid chromatograph (C-Vue), one microfluidic system (PharmaChk), one mass spectrometer (QDa), and one thin layer chromatography kit (GPHF-Minilab). Each device was tested with a series of field collected medicines (FCM) along with simulated medicines (SIM) formulated in a laboratory. The FCM and SIM ranged from samples with good quality active pharmaceutical ingredient (API) concentrations, reduced concentrations of API (80% and 50% of the API), no API, and the wrong API. All the devices had high sensitivities (91.5 to 100.0%) detecting medicines with no API or the wrong API. However, the sensitivities of each device towards samples with 50% and 80% API varied greatly, from 0% to 100%. The infrared and Raman spectrometers had variable sensitivities for detecting samples with 50% and 80% API (from 5.6% to 50.0%). The devices with the ability to quantitate API (C-Vue, PharmaChk, QDa) had sensitivities ranging from 91.7% to 100% to detect all poor quality samples. The specificity was lower for the quantitative C-Vue, PharmaChk, & QDa (50.0% to 91.7%) than for all the other devices in this study (95.5% to 100%).Conclusions: The twelve devices evaluated could detect medicines with the wrong or none of the APIs, consistent with falsified medicines, with high accuracy. However, API quantitation to detect formulations similar to those commonly found in substandards proved more difficult, requiring further technological innovation.Keywords
Funding Information
- Regional Malaria and other Communicable Disease Threats Trust Fund
- Government of Canada
- Government of the United Kingdom
- Asian Development Bank (RETA 8763)
- Wellcome Trust (N°202935/Z/16/Z)
This publication has 13 references indexed in Scilit:
- A New Handheld Device for the Detection of Falsified Medicines: Demonstration on Falsified Artemisinin-Based Therapies from the FieldThe American Journal of Tropical Medicine and Hygiene, 2017
- Fingerprinting of falsified artemisinin combination therapies via direct analysis in real time coupled to a compact single quadrupole mass spectrometerAnalytical Methods, 2016
- Pilot testing of dipsticks as point-of-care assays for rapid diagnosis of poor-quality artemisinin drugs in endemic settingsTropical Medicine and Health, 2016
- Rapid evaluation of artesunate quality with a specific monoclonal antibody-based lateral flow dipstickAnalytical and Bioanalytical Chemistry, 2016
- Responding to the Pandemic of Falsified MedicinesThe American Journal of Tropical Medicine and Hygiene, 2015
- Paper Test Cards for Presumptive Testing of Very Low Quality Antimalarial MedicationsThe American Journal of Tropical Medicine and Hygiene, 2015
- Continuous flow microfluidic solution for quantitative analysis of active pharmaceutical ingredient content and kinetic releaseAnalytical Methods, 2015
- Development of a colloidal gold-based lateral flow dipstick immunoassay for rapid qualitative and semi-quantitative analysis of artesunate and dihydroartemisininMalaria Journal, 2014
- Paper Analytical Devices for Fast Field Screening of Beta Lactam Antibiotics and Antituberculosis PharmaceuticalsAnalytical Chemistry, 2013
- Interval Estimation for a Binomial ProportionStatistical Science, 2001